[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Therapeutics Inc (CMPX)

Compass Therapeutics Inc (CMPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 318,756
  • Shares Outstanding, K 180,088
  • Annual Sales, $ 0 K
  • Annual Income, $ -66,490 K
  • EBIT $ -73 M
  • EBITDA $ -73 M
  • 60-Month Beta 1.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.51

Options Overview Details

View History
  • Implied Volatility 130.43% (+14.73%)
  • Historical Volatility 305.04%
  • IV Percentile 11%
  • IV Rank 6.28%
  • IV High 895.68% on 01/21/26
  • IV Low 79.11% on 08/13/25
  • Expected Move (DTE 14) 0.3910 (20.31%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 6,699
  • Volume Avg (30-Day) 11,419
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 119,797
  • Open Int (30-Day) 79,314
  • Expected Range 1.5340 to 2.3160

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 8
  • High Estimate $-0.09
  • Low Estimate $-0.15
  • Prior Year $-0.12
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6100 +20.81%
on 04/27/26
6.8450 -71.59%
on 04/16/26
-3.4850 (-64.18%)
since 04/01/26
3-Month
1.6100 +20.81%
on 04/27/26
6.8800 -71.73%
on 02/03/26
-4.4550 (-69.61%)
since 01/30/26
52-Week
1.6100 +20.81%
on 04/27/26
6.8800 -71.73%
on 02/03/26
+0.1250 (+6.87%)
since 05/01/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX).  Such investors...

CMPX : 1.9600 (+10.73%)
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median...

CMPX : 1.9600 (+10.73%)
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical...

CMPX : 1.9600 (+10.73%)
Nike Stock Options Alert: LEAPS Buying Hints at a Bull Call Spread

Nike’s options volume on Thursday was its eighth-highest in the past three months. The volume included seven unusually active call options. One of them expiring in 14 months sets up nicely for a Bull...

CRWV : 118.41 (+6.10%)
ADDYY : 87.1900 (+0.74%)
NKE : 44.30 (-0.14%)
CMPX : 1.9600 (+10.73%)
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached...

CMPX : 1.9600 (+10.73%)
Compass Therapeutics Provides Corporate Update

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody)...

CMPX : 1.9600 (+10.73%)
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

CMPX : 1.9600 (+10.73%)
Compass Therapeutics Announces Key Leadership Appointments

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

CMPX : 1.9600 (+10.73%)
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today...

CMPX : 1.9600 (+10.73%)
Compass Therapeutics to Participate in Upcoming December Investor Events

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today...

CMPX : 1.9600 (+10.73%)

Business Summary

Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 1.9867
2nd Resistance Point 1.9033
1st Resistance Point 1.8367
Last Price 1.9600
1st Support Level 1.6867
2nd Support Level 1.6033
3rd Support Level 1.5367

See More

52-Week High 6.8800
Fibonacci 61.8% 4.8669
Fibonacci 50% 4.2450
Fibonacci 38.2% 3.6231
Last Price 1.9600
52-Week Low 1.6100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.